Department of Vascular Surgery, Shandong Provincial Hospital affiliated to Shandong University, 324 Jingwuweiqi Road, Ji'nan 250021, China.
Department of Hemangioma & Vascular Malformation, He'nan Provincial People's Hospital, 7 Weiwu Road, Jinshui District, Zhengzhou 450003, China.
Nanomedicine (Lond). 2017 Nov;12(21):2611-2624. doi: 10.2217/nnm-2017-0130. Epub 2017 Sep 29.
To develop propranolol-loaded poly(lactic-co-glycolic acid) nanoparticle with CD133 aptamers (PPN-CD133) to treat infantile hemangioma.
MATERIALS & METHODS: The antihemangioma activity and mechanism of PPN-CD133 were evaluated.
RESULTS & CONCLUSION: PPN-CD133 are of desired size (143.7 nm), drug encapsulation efficiency (51.8%) and sustained drug release for 8 days. PPN-CD133 could effectively bind to CD133 hemangioma stem cells, resulting in enhanced cytotoxic effect and reduced expression of angiogenesis factors in hemangioma stem cells. The therapeutic effect of PPN-CD133 in hemangioma was superior to that of untargeted PPN and propranolol in vivo, as reflected by reduced hemangioma volume, weight and microvessel density. PPN-CD133 represents a very promising approach to locally and efficiently deliver propranolol leading to significant inhibition of infantile hemangioma.
研制载有 CD133 适体的普萘洛尔聚乳酸-羟基乙酸共聚物纳米粒（PPN-CD133）以治疗婴幼儿血管瘤。
评估 PPN-CD133 的抗血管生成活性及作用机制。
PPN-CD133 的粒径为（143.7±2.7）nm，药物包封率为（51.8±1.2）%，药物可持续释放 8 d。PPN-CD133 能够与 CD133 阳性的血管瘤干细胞有效结合，增强对血管瘤干细胞的细胞毒性作用，降低其血管生成因子的表达。PPN-CD133 在体内对血管瘤的治疗效果优于未靶向 PPN 和普萘洛尔，表现为血管瘤体积、重量和微血管密度降低。PPN-CD133 是一种很有前途的局部给药方法，能够高效递送普萘洛尔，显著抑制婴幼儿血管瘤。
